AR097204A1 - Métodos de tratamiento de tumores sólidos - Google Patents

Métodos de tratamiento de tumores sólidos

Info

Publication number
AR097204A1
AR097204A1 ARP140102910A ARP140102910A AR097204A1 AR 097204 A1 AR097204 A1 AR 097204A1 AR P140102910 A ARP140102910 A AR P140102910A AR P140102910 A ARP140102910 A AR P140102910A AR 097204 A1 AR097204 A1 AR 097204A1
Authority
AR
Argentina
Prior art keywords
solid tumors
treatment methods
composition
pci
tumors treatment
Prior art date
Application number
ARP140102910A
Other languages
English (en)
Inventor
Balasubramanian Sriram
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of AR097204A1 publication Critical patent/AR097204A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición caracterizada porque comprende una cantidad terapéuticamente eficaz de un compuesto inhibidor de la ACK, una cantidad terapéuticamente eficaz de un compuesto inhibidor de HDAC y un excipiente farmacéuticamente aceptable. Reivindicación 5: La composición de la reivindicación 1, caracterizada porque el inhibidor de la ACK es (R)-1-(3-(4-amino-3-(4-fenoxifenil)-1H-pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (es decir, PCI-32765 / ibrutinib), (fórmula (1)). Reivindicación 8: La composición de la reivindicación 1, caracterizada porque el inhibidor de HDAC es 3-[(dimetilamino)metil]-N-{2-[4-(hidroxicarbamoil)fenoxi]etil}-1-benzofuran-2-carboxamida (es decir, PCI-24781 / abexinostat), (fórmula (2)).
ARP140102910A 2013-08-02 2014-08-01 Métodos de tratamiento de tumores sólidos AR097204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361861853P 2013-08-02 2013-08-02

Publications (1)

Publication Number Publication Date
AR097204A1 true AR097204A1 (es) 2016-02-24

Family

ID=52428222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102910A AR097204A1 (es) 2013-08-02 2014-08-01 Métodos de tratamiento de tumores sólidos

Country Status (7)

Country Link
US (1) US9421208B2 (es)
EP (1) EP3027192A4 (es)
JP (1) JP6800750B2 (es)
AR (1) AR097204A1 (es)
CA (1) CA2919996A1 (es)
TW (1) TWI649081B (es)
WO (1) WO2015017812A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2530083T (pt) 2006-09-22 2016-08-01 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US20110224235A1 (en) 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
CN107277527B (zh) * 2010-07-15 2020-02-18 威勒斯媒体国际有限公司 解码装置、解码方法、编码装置以及编码方法
PT2603081T (pt) 2010-08-10 2017-01-13 Celgene Avilomics Res Inc Sal de besilato de um inibidor de btk
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2920180A4 (en) 2012-11-15 2016-04-13 Pharmacyclics Inc PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
JP6429292B2 (ja) 2013-08-12 2018-11-28 ファーマサイクリックス エルエルシー Ｈｅｒ２増幅性癌の処置のための方法
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CR20160203A (es) 2013-09-30 2016-08-31 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN106573002A (zh) 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
KR20170134462A (ko) 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
GB201703876D0 (en) * 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2021247969A1 (en) 2020-06-05 2021-12-09 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
USD905022S1 (en) * 2020-07-22 2020-12-15 Crown Tech Llc Microphone isolation shield
USD910604S1 (en) * 2020-07-22 2021-02-16 Crown Tech Llc Microphone isolation shield

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794063A (fr) 1972-01-17 1973-07-16 Henkel & Cie Gmbh Anti-inflammatoires pour compositions cosmetiques
EP0084236A3 (en) 1981-12-22 1983-08-03 Fbc Limited Fungicidal heterocyclic compounds and compositions containing them
WO1989003819A1 (fr) 1987-10-20 1989-05-05 Otsuka Pharmaceutical Co., Ltd. Derives d'acide phenylcarboxylique
JPH03215470A (ja) 1990-01-22 1991-09-20 Suntory Ltd プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤
DE4124345A1 (de) 1991-07-23 1993-01-28 Gruenenthal Gmbh Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
HUP0102661A2 (hu) 1998-04-17 2001-11-28 Parker Hughes Institute BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
WO2001014331A2 (en) 1999-08-24 2001-03-01 Regents Of The University Of California Non-quinoline inhibitors of malaria parasites
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SK3812002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
MXPA02003364A (es) 1999-10-06 2002-08-23 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las cinasas de tirosina.
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
KR20100035666A (ko) 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
EP1246829A1 (en) 1999-12-17 2002-10-09 Ariad Pharmaceuticals, Inc. Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
HUP0303656A3 (en) 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
EP1345592A2 (en) 2000-12-06 2003-09-24 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
CA2450777C (en) 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
RU2295518C2 (ru) 2001-11-21 2007-03-20 Сьюнесис Фармасьютикалс, Инк. Способ нахождения лигандов
AU2003211362A1 (en) 2002-02-21 2003-09-09 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
RU2005105696A (ru) 2002-08-02 2005-11-10 Арджента Дискавери Лимитед (Gb) Замещенные тиенилгидроксамовые кислоты в качестве ингибиторов гистондеацетилазы
JP2005536533A (ja) 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
DK1611088T3 (da) 2003-04-07 2009-10-19 Pharmacyclics Inc Hydroxymater som terapeutiske midler
WO2005000197A2 (en) 2003-04-11 2005-01-06 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
CN1934113B (zh) 2004-01-26 2011-11-09 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的组合物
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
US7368476B2 (en) 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
JP2008501677A (ja) 2004-06-04 2008-01-24 ファイザー・プロダクツ・インク 異常な細胞増殖を治療する方法
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
BRPI0516166A (pt) 2004-09-28 2008-08-26 Janssen Pharmaceutica Nv antagonista do ccr2 de dipiperidina substituìda
AU2005317047A1 (en) 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
MX2007005643A (es) 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas.
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
ATE492545T1 (de) 2005-05-13 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
US20080261975A1 (en) 2005-11-12 2008-10-23 Joerg Martin Bentzien Tec Kinase Inhibitors
US7933820B2 (en) 2006-01-13 2011-04-26 Data Trace Information Services, Llc Method and apparatus for compiling data from property title documents
WO2007087068A2 (en) 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
US20090317836A1 (en) 2006-01-30 2009-12-24 The Scripps Research Institute Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
MX2008014450A (es) 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
CA2659070C (en) 2006-09-15 2014-10-21 Janssen Pharmaceutica Nv Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
PT2530083T (pt) 2006-09-22 2016-08-01 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
SI2099442T1 (sl) 2006-12-26 2015-03-31 Pharmacyclics, Inc. Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
KR101483805B1 (ko) 2007-01-30 2015-01-16 파마시클릭스, 인코포레이티드 히스톤 데아세틸라제 억제제에 대한 암 내성을 확인하는 방법
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN101902911B (zh) 2007-10-19 2015-12-16 阿维拉制药公司 杂芳基化合物和其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2701275C (en) 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US20110224235A1 (en) * 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CA2773985A1 (en) 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Protein kinase conjugates and inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
UA108889C2 (uk) 2010-06-23 2015-06-25 Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
PT2603081T (pt) 2010-08-10 2017-01-13 Celgene Avilomics Res Inc Sal de besilato de um inibidor de btk
BR112013033534A2 (pt) 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
UY34295A (es) 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
TW201427664A (zh) * 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
MX2016005283A (es) 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
CN103923084B (zh) 2014-01-29 2016-08-17 苏州晶云药物科技有限公司 几种晶型及其制备方法

Also Published As

Publication number Publication date
EP3027192A4 (en) 2017-03-22
EP3027192A1 (en) 2016-06-08
JP2016529245A (ja) 2016-09-23
US9421208B2 (en) 2016-08-23
TWI649081B (zh) 2019-02-01
CA2919996A1 (en) 2015-02-05
WO2015017812A1 (en) 2015-02-05
US20150038518A1 (en) 2015-02-05
TW201601727A (zh) 2016-01-16
JP6800750B2 (ja) 2020-12-16

Similar Documents

Publication Publication Date Title
AR097204A1 (es) Métodos de tratamiento de tumores sólidos
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CO6382125A2 (es) Inhibidores de proteína quinasa
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
CL2013001381A1 (es) Compuestos derivados de hidroxi-amida pirimidina, inhibidores de la proteina deacetilasa hdac6; composicion farmaceutica; combinación farmaceutica; metodos de uso para el tratamiento de una enfermedad proliferativa o cancer; un kit
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
CY2016015I1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
HUE047841T2 (hu) L-dopa, dopa dekarboxiláz inhibitorok, katekol-o-metil transzferáz inhibitorok folyamatos adagolására szolgáló készítmények
ECSP11011151A (es) Compuestos purina
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
NI201200072A (es) Métodos y composiciones para tratar cáncer
MX346186B (es) Inhibidores de proteina cinasas.
NZ621221A (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
PH12015500375A1 (en) Nep inhibitors for treating diseases characterized by atrial enlargemenet or remodeling
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана

Legal Events

Date Code Title Description
FB Suspension of granting procedure